Short Interest in Lipocine Inc. (NASDAQ:LPCN) Increases By 155.6%

Lipocine Inc. (NASDAQ:LPCN) was the recipient of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 278,400 shares, an increase of 155.6% from the March 31st total of 108,900 shares. Currently, 5.4% of the company’s shares are sold short. Based on an average trading volume of 61,900 shares, the days-to-cover ratio is presently 4.5 days.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on shares of Lipocine in a research note on Friday, April 19th. They set a “sell” rating on the stock.

Lipocine Price Performance

Shares of LPCN stock traded up $0.26 during trading hours on Friday, reaching $4.81. 19,754 shares of the stock were exchanged, compared to its average volume of 60,050. The business’s fifty day moving average is $4.58 and its two-hundred day moving average is $3.56. Lipocine has a 12-month low of $2.31 and a 12-month high of $7.15. The firm has a market capitalization of $25.73 million, a P/E ratio of -1.58 and a beta of 1.05.

Lipocine (NASDAQ:LPCN) last released its earnings results on Thursday, March 7th. The specialty pharmaceutical company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.11. The firm had revenue of $0.22 million for the quarter. As a group, equities research analysts predict that Lipocine will post -1.49 earnings per share for the current fiscal year.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.